Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Heidenhain Disease: Challenging Diagnosis of a Creutzfeldt-Jakob Variant.

Created on 02 Oct 2026

Authors

Rafael S Brambilla, Pedro N Fortunato, Rosana C Maffeis, Caroline M Tapajós Bolzani, Hilton M da Silva Júnior

Published in

Cureus. Volume 18. Issue 8. Pages e115516. Epub Aug 31, 2026.

Abstract

Creutzfeldt-Jakob disease (CJD) is a rare disorder caused by prions, characterized by rapid deterioration of cognitive and neurological functions. The Heidenhain variant is an uncommon form in which visual symptoms are prominent at onset due to involvement of the occipital cortex, leading to a delayed diagnosis. We present the case of a 67-year-old woman who initially exhibited decreased visual acuity, followed by difficulties in reaching for and identifying objects, experiencing optic apraxia, psychomotor slowing, perseverative behavior, and impaired judgment. Brain magnetic resonance imaging (MRI) showed diffusion restriction and bilateral cortical T2/fluid-attenuated inversion recovery (FLAIR) hypersignal. Additionally, cerebrospinal fluid (CSF) analysis tested positive for the 14-3-3 protein. The patient experienced a rapid neurological decline and passed away four months after the onset of symptoms. This case report highlights the critical need to recognize the Heidenhain variant in patients presenting with isolated complex visual disturbances, especially when accompanied by early cognitive impairment.

PMID:
42819580
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement